Webster Bank N. A. decreased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 0.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,841 shares of the healthcare product maker’s stock after selling 34 shares during the period. Webster Bank N. A.’s holdings in Abbott Laboratories were worth $479,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Atwood & Palmer Inc. lifted its position in Abbott Laboratories by 157.5% in the first quarter. Atwood & Palmer Inc. now owns 3,270 shares of the healthcare product maker’s stock valued at $145,000 after purchasing an additional 2,000 shares during the period. Independent Portfolio Consultants Inc. lifted its position in Abbott Laboratories by 9.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 3,420 shares of the healthcare product maker’s stock valued at $152,000 after purchasing an additional 292 shares during the period. Farmers National Bank lifted its position in Abbott Laboratories by 1.5% in the first quarter. Farmers National Bank now owns 3,568 shares of the healthcare product maker’s stock valued at $158,000 after purchasing an additional 52 shares during the period. Advantage Investment Management LLC lifted its position in Abbott Laboratories by 17.3% in the first quarter. Advantage Investment Management LLC now owns 3,674 shares of the healthcare product maker’s stock valued at $163,000 after purchasing an additional 543 shares during the period. Finally, Delta Asset Management LLC TN lifted its position in Abbott Laboratories by 1.3% in the first quarter. Delta Asset Management LLC TN now owns 3,996 shares of the healthcare product maker’s stock valued at $178,000 after purchasing an additional 51 shares during the period. Institutional investors and hedge funds own 71.50% of the company’s stock.

In related news, insider Sharon J. Bracken sold 2,000 shares of the stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $49.16, for a total transaction of $98,320.00. Following the completion of the sale, the insider now directly owns 28,806 shares of the company’s stock, valued at $1,416,102.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jaime Contreras sold 52,700 shares of the stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the sale, the insider now directly owns 58,739 shares of the company’s stock, valued at $3,052,665.83. The disclosure for this sale can be found here. Over the last three months, insiders have sold 270,850 shares of company stock valued at $13,549,998. Company insiders own 0.76% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/09/28/webster-bank-n-a-sells-34-shares-of-abbott-laboratories-abt.html.

A number of equities research analysts recently commented on ABT shares. Zacks Investment Research downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday. Wells Fargo & Company restated an “outperform” rating and issued a $54.00 price objective (up previously from $47.50) on shares of Abbott Laboratories in a research report on Friday, June 30th. TheStreet upgraded shares of Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Monday, July 3rd. Barclays PLC restated an “overweight” rating and issued a $57.00 price objective (up previously from $52.00) on shares of Abbott Laboratories in a research report on Saturday, July 22nd. Finally, BMO Capital Markets restated a “hold” rating and issued a $48.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, July 11th. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Abbott Laboratories currently has a consensus rating of “Buy” and an average target price of $53.64.

Shares of Abbott Laboratories (NYSE ABT) traded up 3.289% on Thursday, hitting $53.865. 8,850,780 shares of the stock were exchanged. The company has a market cap of $93.59 billion, a P/E ratio of 75.441 and a beta of 1.06. The firm’s 50-day moving average is $50.15 and its 200-day moving average is $47.04. Abbott Laboratories has a one year low of $37.38 and a one year high of $54.80.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 EPS for the quarter, beating the consensus estimate of $0.60 by $0.02. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. The business had revenue of $6.64 billion during the quarter, compared to analyst estimates of $6.63 billion. During the same period in the prior year, the business earned $0.55 earnings per share. The business’s quarterly revenue was up 24.5% on a year-over-year basis. On average, equities analysts forecast that Abbott Laboratories will post $2.49 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be paid a dividend of $0.265 per share. This represents a $1.06 annualized dividend and a yield of 2.01%. The ex-dividend date of this dividend is Thursday, October 12th. Abbott Laboratories’s dividend payout ratio is presently 149.30%.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.